Go Symbol Lookup
Loading...

Priceline.com Posts Wider Loss on Litigation Expenses

 Text Size  
Published: Tuesday, 8 May 2007 | 4:55 PM ET
By: AP

Online travel agency Priceline.com posted a wider loss for its fiscal first-quarter, weighed down by a hefty litigation charge.

Quarterly loss applicable to common shareholders totaled $16.3 million, or 44 cents a share, compared with a loss $964,000, or 2 cents a share in the prior-year quarter. Results included a $55 million charge for a lawsuit settlement, partially offset by $15.9 million in revenue and $2.8 million in interest income from an excise tax refund.

Excluding one-time items and other benefits and expenses, pro forma net income was 43 cents a share.

Revenue rose 25% to $301.4 million from $241.9 million last year.

Analysts polled by Thomson Financial expected a profit of 33 cents a share on revenue of $283.6 million.

Shares fell $1.25, or 2%, to $62.80 in aftermarket electronic trading, after closing up $1.51, or 2.4%, at $64.05 on Tuesday.

 Print
Online travel agency Priceline.com posted a quarterly net loss due to a $55 million charge related to the settlement of litigation.
  Price   Change %Change
PCLN ---

   
Comments

 

More Comments

 
 

Add Comments

 

Your Comments (Up to 1100 characters):

Remaining characters

Your comments have not been posted yet.

Please review your submission to make sure you are comfortable with your entry.

Your Comments:


                
            
            
        

Featured

U.S. Video

  • Discussing the state of Detroit's economy, with CNBC Contributor Keith Boykin; Heather Higgins, Independent Women's Voice; and Doug Holtz-Eakin, American Action Forum.

  • Larry Kudlow discusses the journalistic merit of a Financial Times article, which triggered a brief sell-off in U.S markets. Larry McDonald, Newedge; Ed Butowsky, Chapwood Investments; and Ron Kruszewski, Stifel Nicolaus join in the discussion later.

  • The Supreme Court ruled today that the FTC can keep challenging "pay to delay" deals between pharmaceutical companies and generic drugmakers. CNBC Contributor Keith Boykin; Heather Higgins, Independent Women's Voice; and Doug Holtz-Eakin, American Action Forum, discuss.